Δ4-Dafachronic Acid
(Synonyms: 3-keto-4-Cholestenoic Acid) 目录号 : GC17515A DAF-12 ligand that controls C. elegans development and lifespan
Cas No.:23017-97-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Δ4-Dafachronic acid is a DAF-12 activator.
Steroid hormone dafachronic acid (DA) has been identified to regulate dauer formation and lifespan in Caenorhabditis elegans via binding to the nuclear receptor DAF-12. DAF-12, an orphan nuclear hormone receptor, regulates dauer larva diapause, reproductive development, fat metabolism, as well as life cycle/longevity in C. elegans. In addition, DAF-12 is needed for entry into dauer by acting as a transcriptional repressor of target genes that favor reproductive development when it is not bound to ligand.
In vitro: Δ4-Dafachronic acid is a racemic version of a sterol-derived hormone acting as a ligand of DAF-12. In a previous study, it was found that there was no significant increase in the Δ4- and Δ4-dafachronic acid concentration in the long-lived glp-1 mutant, nor in the mutants defective in dauer formation [1]. Another previous study provided insights into the molecular interface between DA and IIS pathways and suggested that Δ4- and Δ7-dafachronic acid pathways had unique as well as overlapping biological functions in the control of development and lifespan [2].
In vivo: Up to now, there is no animal in vivo study reported for Δ4-Dafachronic acid.
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Li TM et al. No Significant Increase in the Δ4- and Δ7-Dafachronic Acid Concentration in the Long-Lived glp-1 Mutant, nor in the Mutants Defective in Dauer Formation. G3 (Bethesda). 2015 May 12;5(7):1473-9.
[2] Dumas, K. J.,Guo, C.,Wang, X., et al. Functional divergence of dafachronic acid pathways in the control of C. elegans development and lifespan. Dev.Biol. 340(2), 605-612 (2010).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.412 mL | 12.0598 mL | 24.1196 mL |
| 5 mM | 0.4824 mL | 2.412 mL | 4.8239 mL |
| 10 mM | 0.2412 mL | 1.206 mL | 2.412 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。